Bavarian Nordic A/S (BVNRY)
USD 8.07
(3.2%)
USD 8.07
(3.2%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 14.35 Billion DKK | 15.83% |
| 2022 | 12.39 Billion DKK | 2.5% |
| 2021 | 12.08 Billion DKK | 38.02% |
| 2020 | 8.75 Billion DKK | 24.29% |
| 2019 | 7.04 Billion DKK | 130.23% |
| 2018 | 3.06 Billion DKK | -2.91% |
| 2017 | 3.15 Billion DKK | 11.65% |
| 2016 | 2.82 Billion DKK | 41.95% |
| 2015 | 1.98 Billion DKK | 5.4% |
| 2014 | 1.88 Billion DKK | 29.96% |
| 2013 | 1.45 Billion DKK | -5.65% |
| 2012 | 1.53 Billion DKK | -22.13% |
| 2011 | 1.97 Billion DKK | 34.72% |
| 2010 | 1.46 Billion DKK | 15.42% |
| 2009 | 1.27 Billion DKK | -24.98% |
| 2008 | 1.69 Billion DKK | -2.18% |
| 2007 | 1.73 Billion DKK | 81.48% |
| 2006 | 954.42 Million DKK | 2.78% |
| 2005 | 928.56 Million DKK | 54.22% |
| 2004 | 602.1 Million DKK | 40.29% |
| 2003 | 429.16 Million DKK | 35.09% |
| 2002 | 317.7 Million DKK | 413.46% |
| 2001 | 61.87 Million DKK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 13.62 Billion DKK | -5.1% |
| 2024 Q2 | 14.27 Billion DKK | 4.8% |
| 2023 FY | 14.35 Billion DKK | 15.83% |
| 2023 Q3 | 13.39 Billion DKK | -10.63% |
| 2023 Q2 | 14.99 Billion DKK | 13.75% |
| 2023 Q1 | 13.18 Billion DKK | 6.37% |
| 2023 Q4 | 14.35 Billion DKK | 7.12% |
| 2022 Q1 | 11.99 Billion DKK | -0.81% |
| 2022 FY | 12.39 Billion DKK | 2.5% |
| 2022 Q2 | 12.02 Billion DKK | 0.31% |
| 2022 Q4 | 12.39 Billion DKK | 0.78% |
| 2022 Q3 | 12.29 Billion DKK | 2.22% |
| 2021 Q4 | 12.08 Billion DKK | 19.49% |
| 2021 FY | 12.08 Billion DKK | 38.02% |
| 2021 Q1 | 9.74 Billion DKK | 11.3% |
| 2021 Q2 | 10 Billion DKK | 2.67% |
| 2021 Q3 | 10.11 Billion DKK | 1.09% |
| 2020 Q4 | 8.75 Billion DKK | -7.32% |
| 2020 Q1 | 9 Billion DKK | 27.79% |
| 2020 FY | 8.75 Billion DKK | 24.29% |
| 2020 Q2 | 9.24 Billion DKK | 2.64% |
| 2020 Q3 | 9.45 Billion DKK | 2.26% |
| 2019 Q3 | 2.56 Billion DKK | -4.07% |
| 2019 FY | 7.04 Billion DKK | 130.23% |
| 2019 Q1 | 2.76 Billion DKK | -9.77% |
| 2019 Q2 | 2.67 Billion DKK | -3.25% |
| 2019 Q4 | 7.04 Billion DKK | 174.93% |
| 2018 FY | 3.06 Billion DKK | -2.91% |
| 2018 Q4 | 3.06 Billion DKK | -1.37% |
| 2018 Q3 | 3.1 Billion DKK | -1.66% |
| 2018 Q2 | 3.15 Billion DKK | 4.15% |
| 2018 Q1 | 3.02 Billion DKK | -3.9% |
| 2017 Q3 | 2.91 Billion DKK | -4.95% |
| 2017 Q2 | 3.06 Billion DKK | 6.48% |
| 2017 Q1 | 2.88 Billion DKK | 2.05% |
| 2017 Q4 | 3.15 Billion DKK | 8.11% |
| 2017 FY | 3.15 Billion DKK | 11.65% |
| 2016 Q2 | 2.48 Billion DKK | 33.24% |
| 2016 Q1 | 1.86 Billion DKK | -6.37% |
| 2016 FY | 2.82 Billion DKK | 41.95% |
| 2016 Q4 | 2.82 Billion DKK | 9.32% |
| 2016 Q3 | 2.58 Billion DKK | 4.08% |
| 2015 Q1 | 2.46 Billion DKK | 30.55% |
| 2015 Q3 | 2.13 Billion DKK | -3.67% |
| 2015 Q4 | 1.98 Billion DKK | -7.01% |
| 2015 FY | 1.98 Billion DKK | 5.4% |
| 2015 Q2 | 2.22 Billion DKK | -9.87% |
| 2014 FY | 1.88 Billion DKK | 29.96% |
| 2014 Q2 | 1.25 Billion DKK | -5.79% |
| 2014 Q1 | 1.33 Billion DKK | -8.25% |
| 2014 Q4 | 1.88 Billion DKK | 49.33% |
| 2014 Q3 | 1.26 Billion DKK | 0.69% |
| 2013 Q4 | 1.45 Billion DKK | -0.15% |
| 2013 Q3 | 1.45 Billion DKK | -2.88% |
| 2013 Q2 | 1.49 Billion DKK | 7.8% |
| 2013 Q1 | 1.38 Billion DKK | -9.74% |
| 2013 FY | 1.45 Billion DKK | -5.65% |
| 2012 FY | 1.53 Billion DKK | -22.13% |
| 2012 Q3 | 1.64 Billion DKK | -2.68% |
| 2012 Q2 | 1.68 Billion DKK | -10.42% |
| 2012 Q1 | 1.88 Billion DKK | -4.59% |
| 2012 Q4 | 1.53 Billion DKK | -6.38% |
| 2011 Q3 | 1.84 Billion DKK | -5.03% |
| 2011 Q4 | 1.97 Billion DKK | 7.27% |
| 2011 FY | 1.97 Billion DKK | 34.72% |
| 2011 Q2 | 1.94 Billion DKK | 40.89% |
| 2011 Q1 | 1.37 Billion DKK | -6.14% |
| 2010 Q3 | 1.37 Billion DKK | -12.17% |
| 2010 Q4 | 1.46 Billion DKK | 7.04% |
| 2010 FY | 1.46 Billion DKK | 15.42% |
| 2010 Q1 | 1.44 Billion DKK | 13.47% |
| 2010 Q2 | 1.56 Billion DKK | 8.2% |
| 2009 Q4 | 1.27 Billion DKK | 0.0% |
| 2009 FY | 1.27 Billion DKK | -24.98% |
| 2008 FY | 1.69 Billion DKK | -2.18% |
| 2007 FY | 1.73 Billion DKK | 81.48% |
| 2006 FY | 954.42 Million DKK | 2.78% |
| 2005 FY | 928.56 Million DKK | 54.22% |
| 2004 FY | 602.1 Million DKK | 40.29% |
| 2003 FY | 429.16 Million DKK | 35.09% |
| 2002 FY | 317.7 Million DKK | 413.46% |
| 2001 FY | 61.87 Million DKK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 1.87 Million USD | -764230.681% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -2876070.6% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -5493385.075% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -135897.849% |
| GB Sciences, Inc. | 103.44 Thousand USD | -13875514.354% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -160286.238% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -80275140.492% |
| Skye Bioscience, Inc. | 11.94 Million USD | -120107.026% |
| Zenith Capital Corp. | 7410.00 USD | -193700480.297% |
| Agentix Corp. | 261.39 Thousand USD | -5490968.204% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -732884.048% |
| Biomind Labs Inc. | 73.81 Thousand USD | -19443692.249% |
| ContraFect Corporation | 20.67 Million USD | -69309.609% |
| CSL Limited | 38.02 Billion USD | 62.25% |
| CytoDyn Inc. | 11.13 Million USD | -128790.203% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1862395.913% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -51264.203% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -2986686.791% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -19834368.32% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -4058871.43% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -10923.063% |
| SQZ Biotechnologies Company | 107.18 Million USD | -13290.815% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -433137.58% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -36848.06% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1002196.946% |
| Mesoblast Limited | 667.9 Million USD | -2049.004% |
| Marizyme, Inc. | 22.01 Million USD | -65097.202% |
| Genus plc | 1.02 Billion USD | -1295.006% |
| Pharming Group N.V. | 462.85 Million USD | -3001.024% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -2289088.676% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -3755545.421% |
| IMV Inc. | 31.33 Million USD | -45707.463% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -346092.398% |
| MultiCell Technologies, Inc. | 126.22 USD | -11371583642.672% |
| ONE Bio Corp. | 70.08 Million USD | -20379.574% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -11068.946% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -40700.515% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -990567.243% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -47720.21% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -522531.543% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -2087682.588% |
| Alpha Cognition Inc. | 2.45 Million USD | -585226.996% |
| Enzolytics Inc. | 361.7 Million USD | -3868.192% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | -215.979% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -29989.332% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -2243795.625% |
| Genscript Biotech Corporation | 3.38 Billion USD | -323.851% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -198704.517% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -18798146.326% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -4460106.771% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -5491556.464% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1546647.439% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1056562.959% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -3676760.434% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1527342.909% |
| Helix BioMedix, Inc. | 3.02 Million USD | -474372.891% |
| EV Biologics, Inc. | 431.71 Thousand USD | -3324604.087% |
| Q BioMed Inc. | 3.51 Million USD | -408181.712% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -27135.181% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -3115.982% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -98477.789% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -551268.894% |
| HST Global, Inc. | 1526.00 USD | -940577422.936% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -621351112.121% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1452702.877% |
| Halberd Corporation | 10.13 Thousand USD | -141676072.145% |
| Resverlogix Corp. | 8.11 Million USD | -176772.619% |
| Cell Source, Inc. | 195.17 Thousand USD | -7354073.007% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -63005092.924% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.37 Million USD | -194462.933% |
| Ember Therapeutics, Inc. | 184.00 USD | -7800659139.13% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -23058011.104% |
| Kadimastem Ltd | 2.3 Million USD | -622847.684% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -15004774.709% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -25139517.123% |
| LadRx Corporation | 2.3 Million USD | -621821.441% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -4058871.43% |
| Affymax, Inc. | 7.44 Million USD | -192741.771% |
| Itoco Inc. | 1.4 Million USD | -1025076.777% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -13540666.981% |
| Mobile Lads Corp. | 52.00 USD | -27602332592.308% |
| International Stem Cell Corporation | 5.39 Million USD | -266193.377% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 137.63 Thousand USD | -10428134.209% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -10039077.601% |
| Qrons Inc. | 420.00 USD | -3417431566.667% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -3723451.966% |
| SYBLEU INC | 330.46 Thousand USD | -4343198.897% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -2599554.604% |
| Rebus Holdings, Inc. | 5000.00 USD | -287064160.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -3505625.877% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -95576.414% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -86474.661% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -18168524.051% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1659850.826% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -190843.368% |
| Neutra Corp. | 2851.00 USD | -503444761.452% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -44191.838% |
| PureTech Health plc | 693.97 Million USD | -1968.267% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -177734.899% |
| IXICO plc | 15.84 Million USD | -90491.397% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -173206.122% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -13791.461% |
| CSL Limited | 38.02 Billion USD | 62.25% |
| Cellectis S.A. | 333.99 Million USD | -4197.438% |